Home > Insider Trading > Filing (0001104659-25-003473)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819576	Liquidia Corp	LQDA	Pharmaceutical Preparations (2834)	851710962

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1832592	Scott Moomaw	419 Davis Drive, Suite 100 Morrisville NC 27560	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-01-11	69,729	$0.00	223,856	No	4	A	Direct
Common Stock	Disposition	2025-01-14	8,362	$11.78	215,494	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Units	Acquisiton	2025-01-11	69,729	$0.00	69,729	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
69,729			No	4	A	Direct

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
25% of the RSUs shall vest on January 11, 2026 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter.
Includes (i) 41,666 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 37,292 unvested RSUs of the 49,723 RSUs granted to the Reporting Person on January 11, 2024 and (iii) 9,629 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
These shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 11, 2023 and January 11, 2024.
Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
On January 11, 2025, the Reporting Person was granted 69,729 PSUs. The PSUs shall vest upon the later of (A) the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter, and (B) the first commercial sale of YUTREPIA by the Issuer.